Dilution fuels big runs here in the OTC sewer. Not much to speak of here though. The CEO is shooting herself in the foot on that front. OTC lenders will not enter into a deal with execs that refuse to promote the company. No eyeballs / retail stock buyers means the lender would have little chance of selling share conversions at a good price. That is the only way the lender, along with market makers, can profit on big money deals.
By refusing to update the market on events / progress and maintain a good narrative, IMUN is shutting down all sorts of potentially beneficial avenues.
The term "public" in 'public company' actually means something. ;-)
News 
Market Data 
Discover 
